HCW Biologics Inc (HCWB)vsBeiGene, Ltd. (ONC)
HCWB
HCW Biologics Inc
$3.41
-0.58%
HEALTHCARE · Cap: $3.99M
ONC
BeiGene, Ltd.
$329.80
+0.69%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 86960% more annual revenue ($5.74B vs $6.59M). ONC leads profitability with a 8.9% profit margin vs -34.7%. ONC earns a higher WallStSmart Score of 54/100 (C-).
HCWB
Buy51
out of 100
Grade: C-
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HCWB.
Margin of Safety
+81.0%
Fair Value
$1847.00
Current Price
$329.80
$1517.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 49.4%
Revenue surging 129081.0% year-over-year
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HCWB
The strongest argument for HCWB centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 129081.0% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Debt/Equity.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
HCWB carries more volatility with a beta of 2.30 — expect wider price swings.
HCWB is growing revenue faster at 129081.0% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (54/100 vs 51/100) and 35.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a forward-thinking biotechnology company focused on pioneering immunotherapies and vaccine technologies to tackle pressing health issues such as cancer and infectious diseases. Utilizing its proprietary platforms to amplify immune responses, HCW Biologics is actively expanding a promising pipeline of clinical candidates poised to make significant impacts in patient care. With a keen commitment to strategic partnerships and addressing urgent medical needs, the company aims to establish itself as a competitive force in the biotechnology landscape, presenting compelling investment opportunities that align with the evolving dynamics of the healthcare sector.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?